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101,908 PLN and 99,710 PLN respectively in group I and
53,646 PLN and 65,466 PLN respectively in group II.
PegINF + R in comparison to INF + R was cost-effective
in group I, with ICER 2826 PLN/LYG and 4793
PLN/OALY gained, and dominant in group 2. Changing
in value of key drivers for sensitivity analysis did not have
any signiﬁcant effect on the ICER. CONCLUSION: In
HCV genotype1 infected patients PegINF + R appears to
be cost-effective when compared with INF + R and within
a Polish context offers substantial beneﬁt at reasonable
cost. In HCV genotype non1 infected patients PegINF +
R is more effective and less costly than INF + R.
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Voriconazole is a triazole antifungal recently approved
for the ﬁrst-line treatment of proven or probable invasive
aspergillosis, a nosocomial infection with a high mortal-
ity rate. Conventional amphotericin B (CAB) has long
been the standard therapy for this condition. In a large
randomized clinical trial of primary therapy for invasive
aspergillosis, voriconazole has been shown to be superior
to CAB in terms of global response and survival beneﬁt
as well as fewer adverse events. In this trial, initial ran-
domized therapy could be followed by other licensed anti-
fungal therapy (OLAT) for progression of disease or
intolerance. Voriconazole is also available both intra-
venously and orally. CAB is only available as an intra-
venous formulation. OBJECTIVES: The direct costs and
effectiveness (deﬁned as life year saved) of starting
therapy with voriconazole vs. CAB have been compared
from the Belgian public health care system’s perspective.
METHODS: A decision tree, spanning a 12-week time
horizon, was populated with efﬁcacy and resources use
data, prospectively collected from the large comparative
trial mentioned above as well as from international and
national expert panels. RESULTS: For patients >40kg
(mean = 65kg), the average treatment cost per patient was
€21,298 in the voriconazole arm and €19,492 in the CAB
arm. The incremental cost per life year saved of treating
with voriconazole was €6085. For patients <40kg (mean
= 35kg), the average treatment cost per patient was
€16,863 in the voriconazole arm and €17,111 in the CAB
arm. CONCLUSION: For patients >40kg, the incremen-
tal cost per life year saved of treating with voriconazole
appears to be reasonable compared to its beneﬁt. For
patients <40kg, voriconazole was a dominant therapeu-
tic alternative. An observational study will be initiated in
order to conﬁrm these results.
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OBJECTIVES: To assess the cost-effectiveness and cost-
utility of preventing post-exposure inﬂuenza infection
with the neuraminidase inhibitor oseltamivir from a
health care payer’s perspective in the UK. METHODS:
Based on clinical trial data and data from the literature a
simulation model was developed to predict morbidity and
mortality due to inﬂuenza and it’s speciﬁed complications,
comparing oseltamivir post-exposure prophylaxis for 10
days with no prophylaxis within families. The model was
run for three different attack rates (8%, 12%, 15%).
Robustness of the results was tested by uni- and multi-
variate as well as probabilistic sensitivity analyses.
RESULTS: Post-exposure prophylaxis with oseltamivir
results in reduced morbidity, i.e. less inﬂuenza cases and
hence less hospitalizations and mortality due to inﬂuenza.
However, comparing oseltamivir with no prophylaxis for
the attack rates of 8%, 12%, and 15% the mean costs
per QALY gained are £31,656, £19,264 and £14,241; the
mean costs per case avoided are £468, £291, and £221
respectively. CONCLUSIONS: Post-exposure prophy-
laxis is a valuable intervention particularly in seasons
with higher attack rates such as pandemic situations.
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OBJECTIVES: Invasive aspergillosis is a life-threatening
infection with a very high mortality. Voriconazole (VOR)
is a broad-spectrum triazole that is active against
Aspergillus species. Our objective is to carry out an eco-
nomic evaluation of VOR versus Amphotericin B (AMB)
for the treatment of invasive aspergillosis in Spain.
METHODS: A cost-effectiveness analysis was performed
through a decision analytical model. Effectiveness data
were obtained from a multicenter-randomized trial
showing that VOR was more effective than AMB in treat-
ing invasive aspergillosis in immunosupressed patients
(Herbrecht R, et al. N Engl J Med 2002;347:408–415).
Health care resource utilisation was taken from the afore-
mentioned clinical trial and a local expert panel. Only
direct medical costs were included in the model (drug
acquisition, length of stay, diagnostic procedures and
treatment of therapeutic failures). Drug acquisition costs
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were obtained from ofﬁcial sources, while the rest of data
were taken from a national Health care-cost database.
The perspective selected for this analysis was hospital
assistance and the time horizon chosen was for 12 weeks,
the time that patients were followed up in the referenced
clinical trial. RESULTS: The probability of successful
treatment of VOR was higher than with AMB (52.8 vs.
31.6%, p < 0.05), while the cost/effectiveness ratio was
lower with VOR compared with AMB: €60,577 vs.
€84,294 per each patient with successful outcome. CON-
CLUSIONS: This pharmacoeconomic analysis shows that
VOR is a more efﬁcient therapeutic option than AMB, as
its cost/effectiveness ratio is lower. Therefore, VOR could
be considered as the therapeutic option to be selected rou-
tinely in the treatment of invasive aspergillosis in
immunosupressed patients in Spain.
PIN16
COST-EFFECTIVENESS ANALYSIS OF FUZEON
ADDED TO OPTIMAL STANDARD THERAPY VS.
OPTIMIZED BACKGROUND REGIMEN ALONE IN
PATIENTS WITH HIV/AIDS
Serrano D1, Magaz S1, Badia X2,Alvarez C3, Green J4
1Health Outcomes Policy And Economics, Barcelona, Spain;
2Health Outcomes Research Europe Group, Barcelona, Spain;
3Roche Farma SA, Madrid, Spain; 4Hoffmann-La Roche Inc,
Nutley, NJ, USA
Fuzeon® (enfuvirtide; ENF), formerly know as T-20, is
the ﬁrst drug from a novel class of antiretroviral known
as the HIV fusion inhibitors which has shown high efﬁ-
cacy rates in HIV-1 / AIDS patients who are resistant to
conventional antiretroviral (ARV) agents. OBJECTIVE:
To analyse the efﬁcacy of adding ENF to an optimised
background regimen (OB) in HIV patients. A Markov
model was developed to establish the cost-effectiveness of
ENF in terms of incremental cost per life year gained
(LYG). The model was designed over a time horizon of
10 years with monthly cycles. The analysis was performed
from the perspective of the Spanish NHS. The primary
clinical outcome was time until death. Efﬁcacy rates and
transition probabilities were obtained from reported clin-
ical and epidemiological trials. Resource use data was
retrieved from published literature and from advise from
a panel of 6 clinical opinion leaders. Unit costs for Spain
in Euros 2003 were obtained from published sources.
RESULTS: Adding ENF to OB increases patient’s life
expectancy by 1.6 years (4.6 years with OB vs. 6.2 years
with ENF + OB). Total costs are €116,718 for OB and
€155,674 with ENF + OB, mainly due to the fact that
increasing life expectancy for a given cohort of patients
increases resource use and costs. CONCLUSIONS:
Incremental cost per life year gained with ENF is €24,780.
ENF used in combination with an OB regimen increases
life expectancy for HIV-1 treated patients who are highly
ARV-experienced, resulting in an economically efﬁcient
treatment option.
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OBJECTIVES: In 2004, the concept of diagnosis-related-
groups (DRG) will be implemented in the reimbursement
procedure of German hospitals. Presently, the hospitals
are reimbursed on a daily lump sum basis. To evaluate
the treatment costs of community-acquired pneumonia
(CAP) from the hospital’s perspective, a prospective
health economic study has been in progress since the end
of 2002. An interim analysis revealed ﬁrst cost results.
METHODS: Open, non-randomized prospective obser-
vational study from the perspective of the German hos-
pital administration. From 6 study centres, 84 patients
were enrolled. A total number of 300 patients is foreseen.
A process-cost-analysis was performed to determine the
costs for the German hospital sector starting from the
admission up to the discharge of the patient. The cost cal-
culation comprises diagnostic and therapeutic measures,
drugs, hotel costs and nursing. Both personnel costs and
material costs were included. Due to the dualistic hospi-
tal reimbursement system, acquisition values of medical
devices were not included into the analysis. RESULTS:
The enrolled patients suffered from moderate to severe
stages of CAP with a mean length-of-stay of 11.7 days
(peripheral ward: 11.2; ICU 0.5). Mean costs per patient
amounted to €2204 (SD: €1654). The most important
cost-driving factor was nursing, amounting to mean costs
of €902, followed by hotel costs amounting to €666.
Drug acquisition cost resulted in €291, whereas costs for
diagnostics (€163) and therapeutic measures (€181) were
comparatively low. According to the actual German
ﬁnancing procedure (based on length-of-stay/lump sum
per day), a hospital would be reimbursed with approxi-
mately €2990 per patient with CAP. CONCLUSIONS:
Before the implementation of the DRG system into the
hospital reimbursement procedure, the treatment of CAP
is proﬁtable from the hospital’s perspective. This will
probably change after the implementation of the DRG-
based reimbursement.
